The company's approved product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Adamas Pharmaceuticals also develops novel extended release and combination products for symptomatic treatment of dementia. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States. Adamas Pharmaceuticals' mission is to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers, and society.